A coronary sinus reducer, a small hourglass-shaped device implanted through keyhole surgery, has demonstrated effectiveness in reducing symptoms of refractory angina, a debilitating form of heart disease that affects an estimated 300,000 people in England.
The device works by narrowing a vein at the back of the heart to redirect blood flow to areas of heart muscle receiving insufficient oxygen. A large-scale study examining 491 patients with refractory angina, conducted between 2014 and 2024 across 19 hospitals in England and Scotland, found that 75% of patients experienced significant reductions in chest pain within six months of implantation. The study included 474 patients who received the implant, with most returning home the same day or the day after the procedure. Serious complications were rare according to the research findings.
Refractory angina is characterized by persistent chest pain despite patients having received standard treatments including medications, stents, and bypass surgery. Each device costs the NHS £11,400. Researchers note that despite the apparent success, only a small fraction of the 300,000 people living with refractory angina have received the implant, and it remains an experimental treatment at present.
Consultant cardiologist Dr. Ranil de Silva, who co-led the study, emphasized that the device can substantially improve quality of life and reduce hospitalizations. However, additional trials and NHS funding approval are needed before the coronary sinus reducer can be considered standard treatment for refractory angina. The British Heart Foundation’s clinical director described the findings as reassuring and noted the device offers hope for patients with this challenging condition.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI